https://pharmoniq.com/news/uw-madison-62m-cyclotron-lab-isotope-output PharmoniQ en 2026-11-06T14:06:32.980Z UW-Madison's $62M Cyclotron Lab Aims to Lift Isotope Output Up to 8x cyclotron, medical isotopes, astatine-211, theranostics, Wisconsin https://pharmoniq.com/news/fda-approves-jj-rybrevant-faspro-head-and-neck-cancer PharmoniQ en 2026-11-06T07:57:47.920Z FDA Approves J&J Head and Neck Cancer Shot After 42% Respond FDA, Johnson & Johnson, amivantamab, head and neck cancer, accelerated approval https://pharmoniq.com/news/servier-sevasemten-misses-goal-in-becker-muscular-dystrophy-study PharmoniQ en 2026-11-05T14:09:26.902Z Drug From Servier's $1.55B Deal Misses Goal in 175-Patient Study Servier, Edgewise Therapeutics, Becker muscular dystrophy, clinical trials, rare disease https://pharmoniq.com/news/ultragenyx-cuts-about-20-percent-of-staff-ends-two-rare-disease-drugs PharmoniQ en 2026-11-05T08:04:00.182Z Ultragenyx Cuts About 20% of Staff, Ends Two Rare Disease Drugs Ultragenyx, layoffs, rare disease, gene therapy, restructuring https://pharmoniq.com/blog/pdufa-viii-what-fdas-next-user-fee-deal-changes PharmoniQ en 2026-11-05T10:59:42.384Z PDUFA VIII: What the FDA's Next User Fee Deal Changes PDUFA, FDA, user fees, regulatory affairs, CMC